| CYP2A6 overexpression in human lung cancers correlates with a high malignant status |
Authors: Yoko Matsuda, Keiko Yamakawa, Kousuke Saoo, Kyoko Hosokawa, Masanao Yokohira, Toshiya Kuno, Junko Iwai, Takatoshi Shirai, Kaoru Obika, Tetsuya Kamataki, Katsumi Imaida |
Affiliations:
Onco-Pathology, Department of Pathology and Host-Defense, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa 761-0793, Japan
|
Pages: 53-57 |
Abstract:
CYP2A6 is a major phase I enzyme metabolizing tobacco-specific nitrosamines, implicated as risk factors for lung cancer. In this study, immunohistochemistry and in situ hybridization (ISH) for CYP2A6 with human lung cancer tissues (n=31) obtained by surgical resection showed significantly higher immunoreactivity in the cases with lymph node metastasis. The adenocarcinoma cases (n=23) with lymph node metastasis or large tumor size showed a high immunoreactivity for CYP2A6. The squamous cell carcinoma cases (n=6) with large tumor size showed a tendency for low CYP2A6 immunoreactivity. ISH for CYP2A6 revealed mRNA expression in both adenocarcinoma and squamous cell carcinoma cells. The data suggest that CYP2A6 could have an important role in the development and proliferation of lung carcinomas. With adenocarcinomas, CYP2A6 could be a target candidate for therapeutic and chemopreventive intervention.
|
|
|
|
|
